Feasibility randomised controlled trial of Spring PGD, a digital guided therapy for prolonged grief disorder

Digital guided self-help for Prolonged Grief Disorder (PGD)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN87760956

Enrollment

Registered

2025-02-28

Start date

2025-01-10

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prolonged Grief Disorder (PGD) Mental and Behavioural Disorders

Interventions

Participants will be randomised in a 1:1 ratio to receive immediate guided self-help treatment (Spring PGD) or to a waiting list control group. After a period of 11 weeks on the waiting list, particip

Eligibility

Sex/Gender

All

Age

16 Years to 135 Years

Inclusion criteria

Inclusion criteria: 1. Aged 16 years or over with no upper age limit 2. Diagnosis of PGD 3. PGD is the primary diagnosis 4. Regular access to the internet to complete the digital programme 5. Ability to comply with the requirements of the study

Exclusion criteria

Exclusion criteria: 1. Inability to understand spoken and/or written English 2. Inability to provide valid informed consent 3. Currently engaged in a course of psychological therapy 4. Change in psychotropic medication in the last 4 weeks 5. Current psychosis 6. Substance dependence 7. Active suicide risk

Design outcomes

Primary

Measure	Time frame
Prolonged grief measured using Prolonged Grief 13 Revised (PG-13-R) at baseline and 11 and 22 weeks after randomisation	—

Secondary

Measure	Time frame
1. Traumatic stress symptoms measured using the International Trauma Questionnaire (ITQ) at baseline and 11 and 22 weeks after randomisation 2. Anxiety measured using the Generalised Anxiety Disorder 7 (GAD-7) at baseline and 11 and 22 weeks after randomisation 3. Symptoms of depression measured using Patient Health Questionnaire – 9 (PHQ-9) at baseline and 11 and 22 weeks after randomisation 4. Progress towards goals assessed using Goal Based Outcomes (GBOs) at baseline and 11 and 22 weeks after randomisation 5. Functional impairment measured using the Work and Social Adjustment Scale (WSAS) at baseline and 11 and 22 weeks after randomisation 6. Health-related quality of life measured using EQ5D-5L at baseline and 11 and 22 weeks after randomisation	—

Measure

Time frame

1. Traumatic stress symptoms measured using the International Trauma Questionnaire (ITQ) at baseline and 11 and 22 weeks after randomisation 2. Anxiety measured using the Generalised Anxiety Disorder 7 (GAD-7) at baseline and 11 and 22 weeks after randomisation 3. Symptoms of depression measured using Patient Health Questionnaire – 9 (PHQ-9) at baseline and 11 and 22 weeks after randomisation 4. Progress towards goals assessed using Goal Based Outcomes (GBOs) at baseline and 11 and 22 weeks after randomisation 5. Functional impairment measured using the Work and Social Adjustment Scale (WSAS) at baseline and 11 and 22 weeks after randomisation 6. Health-related quality of life measured using EQ5D-5L at baseline and 11 and 22 weeks after randomisation

—

Countries

United Kingdom, Wales

Contacts

Public ContactCatrin Lewis

LewisCE7@Cardiff.ac.uk+44 (0)2920688357

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026